Autopsy report · NCT06199037
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Cause of deathFunding or business
“Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years before it stopped.
- 46 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Alzheimer's Disease
- Interventions
- SHR-1707; SHR-1707 placebo
- Participants
- 46
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
“Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
“Sponsor decision to terminate the study” - Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
“The Sponsor chose to terminate this study for commercial reasons.” - A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
“Voluntarily terminate the study since the sponsor's development strategy was adjusted.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.